Test Price
6,000 AED✅ Home Collection Available
Lung Cancer Panel 8 (EGFR, BRAF, ALK, ROS1, MET, PD‑L1) – 6000 AED | Precision Molecular Profiling for NSCLC in Dubai
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – Formalin‑Fixed Paraffin‑Embedded (FFPE) tumor blocks or biopsy slides are collected from hospital pathology archives under strict chain of custody.
- Clinical Guidance: Telephonic Post‑Test Clinical Interpretation by Board‑Certified Oncologists with actionable treatment recommendations.
- Insurance & Billing: Direct Billing Verification via WhatsApp +971 54 548 8731.
This panel integrates targeted genomic sequencing and immunohistochemistry to detect actionable alterations in advanced non‑small cell lung cancer, enabling timely initiation of tyrosine kinase inhibitors or immunotherapy in line with NCCN and current DHA guidelines.
Test Overview & Methodology
The Lung Cancer Panel 8 (EGFR, BRAF, ALK, ROS1, MET, PD‑L1) is a targeted genomic and immunohistochemistry assay designed to detect actionable alterations in advanced non‑small cell lung cancer (NSCLC). Performed on formalin‑fixed paraffin‑embedded tumor tissue, this panel delivers clinical‑grade results in 5–7 working days, enabling timely initiation of tyrosine kinase inhibitors or immunotherapy in line with NCCN and current DHA guidelines. Each biomarker is assessed using the most appropriate technology: Fluorescence In Situ Hybridization (FISH) for gene rearrangements, Sanger sequencing for point mutations, and Immunohistochemistry (IHC) for protein expression.
| Feature | Our Lung Cancer Panel 8 (UAE) | Closest Alternative (Single‑Gene Sequencing) |
|---|---|---|
| Precision & Scope | Multi‑gene panel (EGFR, BRAF, ALK, ROS1, MET, PD‑L1) using FISH, Sanger sequencing, and IHC | Single gene (e.g., EGFR) Sanger sequencing only |
| Methodology | Fluorescence In Situ Hybridization (FISH) for ALK/ROS1 rearrangements; Sanger sequencing for mutations; Immunohistochemistry for PD‑L1 | Sanger sequencing; no FISH or IHC integration |
| Turnaround Time | 5–7 working days | 7–10 working days |
| Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139), DHA‑Licensed Facility (No. 1143) | Variable, often lacking UAE‑specific lab licensing |
| Integration | Comprehensive report with oncologist‑curated interpretation and actionable recommendations | Raw genetic variant list without clinical correlation |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor – Specialist Diagnostic Radiology | DHA Registration ID: 61713011
“Every lung cancer journey is unique; this test reveals the molecular signature, but results must be correlated with your complete clinical picture by a multidisciplinary team. We are committed to guiding you with evidence‑based precision.”
Advisory – Medication Continuity
Do Not Alter Prescribed Treatment
Do not discontinue, pause, or modify any prescribed medication without explicit consultation with your treating physician. Abrupt changes may compromise clinical outcomes or interfere with test interpretation.
Exclusion Criteria & Emergency Red Flags
When This Test Is Not Appropriate
- Exclusion: Not suitable for individuals without a histologically confirmed diagnosis of lung cancer. Not indicated for patients currently undergoing surgery or those with acute medical instability.
- Red Flags: Seek immediate medical attention if you experience acute respiratory distress, sudden severe chest pain, or hemoptysis (coughing up blood) unrelated to known conditions.
- All patient data is protected under the UAE Personal Data Protection Law (PDPL) and stored in encrypted, DHA‑compliant servers.
Patient FAQ & Clinical Guidance
1. What does the Lung Cancer Panel 8 test include?
This test detects mutations and rearrangements in EGFR, BRAF, ALK, ROS1, and MET, plus PD‑L1 protein expression in tumor tissue. It is designed to guide targeted therapy or immunotherapy decisions in non‑small cell lung cancer (NSCLC).
2. How long does it take to receive my results?
Your full report is ready in 5 to 7 working days from the date the laboratory receives the FFPE tissue specimen. The report includes comprehensive interpretation by our oncology specialists and direct communication upon request.
3. Is a prescription required to order this test?
Yes, a valid prescription from your treating oncologist or pulmonologist is required. This ensures appropriate clinical context and safe utilization of molecular findings in your treatment plan.
4. Can this test be performed on a blood sample instead of tumor tissue?
No. This panel is validated exclusively on formalin‑fixed paraffin‑embedded (FFPE) tumor tissue blocks or biopsy slides. A tissue specimen is required for accurate FISH, sequencing, and IHC analysis. Circulating tumor DNA (liquid biopsy) is a separate test offering.
UAE Regulatory & Data Privacy Adherence
- Data Protection: All personal and genetic data are processed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Laboratory Licensing: DNA Labs UAE is fully licensed by the Dubai Health Authority (DHA Facility License No. 1143) and operates under ISO 9001:2015 quality management (Cert: INT/EGQ/2509DA/3139).
- Clinical Safety: All diagnostic procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring patient consent and clinical governance standards are strictly maintained.
- Data Security: Genetic data is encrypted at rest and in transit, stored on UAE‑based servers, and never shared with third parties without explicit patient consent.
Clinical & Logistical Metadata
| Test Name | Lung Cancer Panel 8 (EGFR, BRAF, ALK, ROS1, MET, PD‑L1) |
| Price (AED) | 6,000 AED |
| Turnaround Time | 5–7 working days from specimen receipt |
| Sample Type / Matrix | Formalin‑Fixed Paraffin‑Embedded (FFPE) Tumor Tissue Block or Biopsy Slides – Secure Medical Courier Solid Tissue Specimen Retrieval |
| Methodology Used | Fluorescence In Situ Hybridization (FISH) for ALK/ROS1 rearrangements; Sanger sequencing for EGFR/BRAF/MET mutations; Immunohistochemistry (IHC) for PD‑L1 expression |
| ICD-10-CM Code | C34.90 (Malignant neoplasm of unspecified part of unspecified bronchus or lung) |
| LOINC Code | 104196-4 (Lung cancer comprehensive gene panel) |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians